Emergent BioSolutions Expands Supply of TEMBEXA Antiviral
Emergent BioSolutions Inc. has recently announced a significant development in its commitment to public health. The company has successfully secured a $17 million contract modification aimed at bolstering the supply of TEMBEXA® (brincidofovir), an oral antiviral medication specifically approved for the treatment of smallpox. This pivotal step was taken in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which plays a crucial role in the U.S. government’s healthcare emergency preparedness.
Importance of TEMBEXA and the Contract Modification
The new contract modification not only reinforces Emergent's position as a vital supplier during health crises but also responds to the increasing demand for medical countermeasures against diseases such as smallpox. This follows the recent approval from the U.S. Food and Drug Administration (FDA) for the production increase of TEMBEXA's oral suspension formulation, an essential addition for patients who may face challenges swallowing pills. By offering a liquid formulation, the treatment can reach a broader patient demographic, including young children and individuals with certain medical conditions.
Statements from Emergent Leadership
Paul Williams, the senior vice president and head of products business at Emergent, highlighted the importance of their ongoing partnership with BARDA. "Our collaboration reaffirms the critical need for a steady supply of essential countermeasures to safeguard vulnerable populations during potential outbreaks," he stated. The assurance to increase manufacturing processes reflects Emergent's unwavering dedication to health security.
About TEMBEXA
TEMBEXA is an oral antiviral that received FDA approval in June 2021 as an effective treatment for smallpox. It is a key component in preparing the health sector against outbreaks of this historically significant virus. The oral suspension is available in a 10 mg/mL dosage, to be administered once per week for a two-week duration. This formulation's accessibility substantially enhances treatment options for individuals dealing with swallowing difficulties.
Safety and Potential Side Effects
As with any medical treatment, understanding the safety profile and possible side effects is critical. The most frequently reported adverse reactions in clinical studies were gastrointestinal issues, including diarrhea, nausea, and abdominal pain. Patients are advised to consult healthcare providers regarding any discomfort experienced during treatment. A boxed warning specifies that an increased risk for mortality was observed when TEMBEXA was used for an extended period in clinical trials, reinforcing the need for careful monitoring by healthcare professionals.
Commitment to Public Health
Emergent BioSolutions has consistently demonstrated its commitment to public health preparedness. With investments in advanced manufacturing capabilities and active collaborations with governmental bodies, the company aims to ensure timely responses to health emergencies. This latest contract reflects not only a business commitment but also a governance responsibility towards the public's health and safety.
Frequently Asked Questions
What is TEMBEXA?
TEMBEXA is an oral antiviral medication that has been approved for the treatment of smallpox, particularly important during potential outbreaks.
Why is the recent contract significant?
The recently secured contract modification reinforces the supply chain for TEMBEXA, ensuring that the U.S. government can respond effectively to health emergencies.
What are the common side effects of TEMBEXA?
Common side effects include gastrointestinal issues such as diarrhea, nausea, and abdominal pain.
Who can benefit from TEMBEXA?
The oral suspension form of TEMBEXA is advantageous for patients who have difficulty swallowing, such as young children and certain individuals with disabilities.
How does Emergent BioSolutions contribute to public health?
Emergent focuses on producing and distributing critical countermeasures to health threats, partnering with government agencies to enhance healthcare preparedness.
